Recent research from New South Wales reveals significant challenges surrounding opioid agonist treatment access that prevent individuals from receiving and maintaining crucial medical care. This comprehensive study, which Maud Groothuizen conducted as part of her master’s thesis at Vrije Universiteit Amsterdam in collaboration with the National Drug and Alcohol Research Centre, provides critical insights into why many people struggling with opioid dependence face difficulties accessing appropriate treatment.

About the Research

This mixed-methods study explored how people engage with opioid agonist treatment (OAT) in NSW and examined the factors that shape their treatment journeys. The research drew on survey data and lived experience narratives to investigate how individuals navigate entry into treatment, their experiences within services, and the factors that influence ongoing engagement or early treatment discontinuation.

Maud Groothuizen, a master’s student in Global Health with a BSc in Sociology, brings extensive experience in mental health and addiction care research. She previously conducted research on non-medical prescription opioid use amongst young adults in Denmark and worked as a programme assistant at the Trimbos Institute. NDARC, UNSW Sydney hosted her whilst she worked on this thesis focusing on barriers and facilitators to opioid agonist treatment access.

The Scale of the Problem

The Australian Institute of Health and Welfare reports that approximately half of all drug-induced deaths in Australia result from opioids. This stark statistic underscores the urgent need for accessible treatment pathways for those affected by opioid use disorders. Although healthcare professionals recognise opioid agonist treatment as a key evidence-based response to opioid dependence, retention rates remain concerningly low, with global data showing that fewer than 60% of patients remain in treatment after one year.

Identifying Key OAT Engagement Barriers

The research identified several critical challenges that impede both access to and retention in treatment programmes:

Limited Healthcare Provider Capacity

Insufficient numbers of qualified prescribers create one of the most significant OAT engagement barriers. In Australia, general practitioners need additional accreditation to treat larger numbers of patients with opioid dependence. However, this training remains voluntary, and many practitioners choose not to pursue it. As a result, only 20% of available prescribers serve more than 80% of patients, creating substantial strain on the healthcare system and resulting in prolonged waiting times.

Lack of Clear Information and Navigation Support

The study revealed that both patients and support workers often find the treatment system opaque and difficult to navigate. Many individuals remain unaware of available services, eligibility criteria, or how to access treatment. This lack of centralised information creates confusion and can result in missed opportunities for intervention when individuals feel motivated to seek help, significantly impacting opioid agonist treatment access.

Addressing OAT Engagement Barriers in Patient Care

Medication Choice and Patient Autonomy

Research findings highlighted the importance of shared decision-making regarding medication options. When patients lack input into their treatment choices, engagement and satisfaction decrease significantly. The study found that patient autonomy in medication selection proves crucial for maintaining long-term treatment engagement and improving opioid agonist treatment access.

Implementation of Monitoring Requirements

Whilst monitoring measures such as urine drug screening serve important safety functions, their implementation can significantly impact treatment experiences. When healthcare providers apply these punitively rather than as tools for individualised care, these requirements can create stigmatising environments that deter patients from continuing treatment.

Addressing Systemic Issues

The research emphasised that successful treatment outcomes depend not only on medication efficacy but also on the quality of interpersonal care and flexibility in service design. Healthcare providers must consider patients’ broader social needs, including housing stability and access to healthcare benefits, as these factors significantly influence treatment engagement.

Geographic and Economic Barriers

Rural and remote areas face particular challenges in accessing qualified healthcare providers who understand opioid dependence treatment. Additionally, individuals without adequate healthcare coverage or those experiencing homelessness encounter additional OAT engagement barriers that require attention for successful treatment outcomes.

Policy Implications and Recommendations

The study’s findings suggest several areas for improvement to enhance opioid agonist treatment access:

• Clarifying eligibility criteria and available treatment options
• Strengthening patient autonomy within treatment programmes
• Providing additional support for healthcare workers in addiction treatment settings
• Developing clearer guidelines for treatment requirements to encourage pragmatic rather than punitive approaches
• Offering enhanced support for individuals experiencing socioeconomic hardship

Moving Forward

This research underscores the complexity of OAT engagement barriers and the need for comprehensive approaches that address both systemic and individual factors. By understanding these challenges, healthcare systems can work towards creating more accessible, patient-centred treatment environments that support long-term recovery outcomes.

The findings demonstrate that whilst effective treatments exist, removing barriers to access and retention remains essential for addressing the opioid crisis effectively. This requires coordinated efforts across healthcare systems, policy development, and community support services to improve opioid agonist treatment access.

Source: UNSW